Plus   Neg

Aviva To Sell Majority Of Stake In Aviva Singapore

Aviva plc (AV.L,AV) has agreed to sell a majority shareholding in Aviva Singapore to a consortium led by Singapore Life Ltd.

The Singlife consortium includes TPG, a global alternative asset firm, which will become the largest shareholder in the new group upon completion, Sumitomo Life, a Japanese insurer, and other existing Singlife shareholders.

Aviva Investors' operations and clients in Asia will not be impacted by the transaction, Aviva said in a statement.

On completion, Aviva will receive S$2.7 billion or 1.6 billion pounds in consideration, which is comprised of S$2.0 billion or 1.2 billion pounds in cash and marketable securities, S$250 million in vendor finance notes and a 25% equity shareholding in the new group.

Aviva said that it will use proceeds from the sale to further strengthen its central liquidity and will be considered as part of the company's broader capital management and debt reduction objectives.

The company expects to complete the transaction by January 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart and Sam's Club announced options for customers to safely dispose unused, unwanted and expired medication throughout the year. With this, the retail giant aims to help the public from potential danger for misuse and abuse of prescription medications. On Saturday, October 24, the company will host in-person medication disposal events at select store and club locations across U.S. Telecom giant AT&T, Inc. reported Thursday a 24 percent decline in profit for the third quarter, primarily hurt by lower revenues across all its operating segments amid the impact from COVID-19 pandemic. Adjusted earnings for the quarter met analysts' expectations, while quarterly revenues topped their estimates. A Brazilian volunteer, who participated in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University, has died, Brazilian health authority Anvisa said. Oxford university reportedly confirmed the plan to continue the trial after careful assessment that there have been no concerns about safety of the clinical trial.
Follow RTT